JP2024525254A - ウロデシン塩 - Google Patents

ウロデシン塩 Download PDF

Info

Publication number
JP2024525254A
JP2024525254A JP2024503814A JP2024503814A JP2024525254A JP 2024525254 A JP2024525254 A JP 2024525254A JP 2024503814 A JP2024503814 A JP 2024503814A JP 2024503814 A JP2024503814 A JP 2024503814A JP 2024525254 A JP2024525254 A JP 2024525254A
Authority
JP
Japan
Prior art keywords
urodesine
salt
hemi
glutarate
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024503814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525254A5 (https=
Inventor
ハン，ヤオ
チャイ，シエンフォン
リウ，ジュアン
ルオ，チウホン
マーリング，トーマス
Original Assignee
レーボロック・イミュノロジー・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レーボロック・イミュノロジー・アクチェンゲゼルシャフト filed Critical レーボロック・イミュノロジー・アクチェンゲゼルシャフト
Publication of JP2024525254A publication Critical patent/JP2024525254A/ja
Publication of JP2024525254A5 publication Critical patent/JP2024525254A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/12—Glutaric acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2024503814A 2021-07-20 2022-07-20 ウロデシン塩 Pending JP2024525254A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2110403.9A GB202110403D0 (en) 2021-07-20 2021-07-20 Ulodesine Salt
GB2110403.9 2021-07-20
PCT/EP2022/070369 WO2023001893A1 (en) 2021-07-20 2022-07-20 Ulodesine salt

Publications (2)

Publication Number Publication Date
JP2024525254A true JP2024525254A (ja) 2024-07-11
JP2024525254A5 JP2024525254A5 (https=) 2025-07-29

Family

ID=77443478

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024503814A Pending JP2024525254A (ja) 2021-07-20 2022-07-20 ウロデシン塩

Country Status (9)

Country Link
EP (1) EP4373579A1 (https=)
JP (1) JP2024525254A (https=)
KR (1) KR20240038017A (https=)
CN (1) CN117897383A (https=)
AU (1) AU2022314207A1 (https=)
CA (1) CA3226849A1 (https=)
GB (1) GB202110403D0 (https=)
MX (1) MX2024000936A (https=)
WO (1) WO2023001893A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202218782D0 (en) 2022-12-13 2023-01-25 Mehrling Thomas Purine nucleoside phosphorylase inhibitor for metabolic syndrome
WO2025250900A1 (en) * 2024-05-30 2025-12-04 Caamtech, Inc. 4-hydroxy-n,n-diisopropyltryptaminium hydroglutarate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539783B1 (en) 2002-08-21 2011-04-13 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside phosphorylases and nucleosidases
NZ595590A (en) * 2009-03-24 2013-11-29 Biocryst Pharm Inc Useful pharmaceutical salts of 7-[(3r,4r)-3-hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one

Also Published As

Publication number Publication date
CA3226849A1 (en) 2023-01-26
CN117897383A (zh) 2024-04-16
EP4373579A1 (en) 2024-05-29
KR20240038017A (ko) 2024-03-22
AU2022314207A1 (en) 2024-01-18
GB202110403D0 (en) 2021-09-01
WO2023001893A4 (en) 2023-03-30
WO2023001893A1 (en) 2023-01-26
MX2024000936A (es) 2024-06-19

Similar Documents

Publication Publication Date Title
US8501753B2 (en) Useful pharmaceutical salts of 7-[(3R, 4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3, 5-dihydro-pyrrolo [3, 2-D] pyrimidin-4-one
CN105209437B (zh) 心肌肌球蛋白激动剂的盐和制备盐的方法
US7956048B2 (en) Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof
KR20130042498A (ko) 닐로티닙 염 및 이의 결정형
KR20180030964A (ko) 이브루티닙과 카복실산의 공결정체
US12448366B2 (en) Solid forms of pralsetinib
JP2024525254A (ja) ウロデシン塩
CN113840604A (zh) Jak2抑制剂的结晶形式
JP6934945B2 (ja) Ｐ２ｘ３アンタゴニストの結晶塩および多形
TW202444710A (zh) 一種脂蛋白化合物晶型及其製備方法
KR20250130412A (ko) 화합물 a의 염과 결정형, 및 그 제조 방법과 용도
EP4132909B1 (en) Organic acid addition salts of s-pindolol
US12202834B2 (en) Solid state forms of oclacitinib maleate
US20240391933A1 (en) Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide
JP2021529764A (ja) （ｓ）−（５−シクロブトキシ−２−メチル−６−（１−（ピペリジン−４−イル）−１ｈ−ピラゾール−４−イル）−３，４−ジヒドロキノリン−１（２ｈ）−イル）（シクロプロピル）メタノンの塩およびその固体形態
US20260109685A1 (en) Solid forms of pralsetinib
CN114206445B (zh) 咪唑吡啶甲酰胺类化合物的不同形式
US20240217961A1 (en) (S)-Mepazine Salt Forms, Process of Preparing, and Formulations Thereof
CN117105871B (zh) 一种吉非替尼药物共晶体
WO2025012389A1 (en) Salts of (s)-1-(1-(3-chlorophenyl)-2-(dimethylamino)ethyl)-4-(5- morpholino-1h-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2(1h)-one, their preparation and their use as erk kinase inhibitors
WO2017029408A1 (en) Solid state forms of sofosbuvir
CN121039115A (zh) 一种嘧啶并氮杂环类化合物的晶型及其制备方法及应用
HK40062038B (zh) 呋喃并咪唑并吡啶类化合物的合成方法、多晶型物、及盐的多晶型物
CN116178277A (zh) 氯比普兰甲磺酸盐晶型及其制备方法
HK1219484B (zh) 心肌肌球蛋白激动剂的盐和制备盐的方法

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A525

Effective date: 20240318

A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20240318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250718

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250718

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20260309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260309